METHODS USING PHYTOTHERAPY AND NATURAL SUBSTANCES IN THE TREATMENT OF NEURODERMATITIS

Abstract

Background: Neurodermatitis, a chronic inflammatory skin disorder, is characterized by intense pruritus and recurrent eczematous lesions. Conventional treatments often provide only temporary relief and may have adverse side effects. Phytotherapy and natural substances, with their anti-inflammatory and immunomodulatory properties, are emerging as promising alternatives or adjuncts in the treatment of neurodermatitis. Objectives: This study investigates the efficacy of various phytotherapeutic agents and natural compounds in the management of neurodermatitis. We evaluated clinical outcomes, quality-of-life improvements, and safety profiles associated with these treatments in a pediatric and adult population. Methods: A randomized, controlled trial was conducted over 18 months in which 120 patients with neurodermatitis were assigned to either a phytotherapy group or a conventional treatment group. Clinical outcomes were measured using the Eczema Area and Severity Index (EASI), Dermatology Life Quality Index (DLQI), and patient-reported symptom scores. Laboratory assessments of inflammatory markers were also performed. Three tables are provided to summarize patient demographics, treatment outcomes, and the phytotherapeutic agents used. Results: Patients receiving phytotherapy exhibited significant improvements in EASI scores and DLQI ratings compared to the conventional treatment group (p < 0.01). The phytotherapy group demonstrated a faster onset of symptom relief and a reduced recurrence rate over the follow-up period. Laboratory analyses revealed a marked decrease in pro-inflammatory cytokines, including IL-4 and IL-13, among patients in the phytotherapy arm. Safety profiles were favorable, with minimal adverse events reported. Conclusion: The findings indicate that phytotherapy and natural substances can serve as effective and safe alternatives or complementary treatments for neurodermatitis. The integration of these modalities into standard clinical practice may enhance patient outcomes and reduce dependency on corticosteroids and immunosuppressive agents. Further large-scale studies are warranted to confirm these results and optimize treatment protocols.